I’m not going to report record revenue, but it was nonetheless a robust year," CEO Bernard Arnault said during the earnings ...
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, ...
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Meanwhile, Wisconsin Supreme Court race could determine the future of abortion in the state; Minnesota will implement insulin price cap; Denver hospital opens its free naloxone vending machine; and ...
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
This is not your grandfather’s Lego. But perhaps your father still plays with the delightful little bricks. Lego is not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback